Renal Biomarkers Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 1.5 Billion |
| Market Size (2029) | USD 2.20 Billion |
| CAGR (2024 - 2029) | 7.53 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Renal Biomarkers Market Analysis
The Renal Biomarkers Market size is estimated at USD 1.5 billion in 2024, and is expected to reach USD 2.20 billion by 2029, growing at a CAGR of 7.53% during the forecast period (2024-2029).
The key factors propelling the growth of the studied market are the rising prevalence of various kidney-related diseases and diseases such as diabetes and high blood pressure, which are the leading causes of renal diseases, coupled with rapid technological advancements in the field of genetics.
The growing burden of various kidney-related health conditions has been on the rise in recent years. The rising prevalence of kidney diseases such as glomerulonephritis, kidney failure, polycystic kidney disease, lupus nephritis, and analgesic nephropathy, kidney infections, among others, are expected to increase the demand for the diagnostics tests used for the identification of renal biomarkers that are used for the diagnosis of these diseases, which ultimately drive the studied market over the forecasted period. For instance, according to the American Kidney Fund Organization Updated data in 2024, around 37 million Americans have kidney disease. Kidney disease is growing at an alarming rate. Hence, the high prevalence of kidney-related diseases in different countries worldwide is expected to boost the studied market over the forecast period.
The rising prevalence of diabetes cases can lead to an increasing prevalence of kidney-related diseases, which is expected to drive the studied market over the forecasted period. For instance, as per the 2022 update from the International Diabetic Federation (IDF), approximately 537 million adults (20-79 years) will be living with diabetes across the globe in 2021, and the number is projected to rise to 643 million by 2030 and 783 million by 2045. Hence, the significant increase in diabetes that can lead to kidney diseases and the huge role of renal biomarkers testing in diagnosing and managing these diseases are expected to drive the studied market over the forecast period.
Additionally, strategic activities by market players, such as partnerships, mergers and acquisitions, and product launches and approvals, are expected to propel the market's growth. For instance, in June 2023, Renalytix PLC reported that the United States Food and Drug Administration (FDA) had granted De Novo marketing authorization for its KidneyIntelX.dkd prognostic test. This affirms KidneyIntelX as a first-in-class, artificial intelligence-enabled prognostic testing platform to guide care management for adults with type 2 diabetes and early-stage chronic (diabetic) kidney disease. Renalytix believes FDA authorization will increase test adoption, inform clinical guidelines, expand insurance coverage, and pursue additional international regulatory approvals.
Similarly, in August 2023, SphingoTec GmbH and Boditech Med Inc. entered into a development agreement aimed at developing the kidney function biomarker penKid. The MDA solidifies the partnership between SphingoTec GmbH and Boditech Med Inc., aiming to support the successful commercialization of the assay for the biomarker penKid on the AFIAS (Automated Fluorescent Immunoassay System) platforms. Such strategic initiatives are projected to drive the market growth significantly over the forecast period.
Thus, due to the aforementioned factors, such as the growing burden of kidney diseases and strategic activities by market players, the renal biomarkers market is expected to grow at a significant rate during the forecast period. However, regulatory and reimbursement system issues may hamper the market's growth over the forecast period.
Renal Biomarkers Market Trends
Neutrophil Gelatinase-Associated Lipocalin (NGAL) is Expected to Project Significant Growth Over the Forecast Period
NGAL (Neutrophil Gelatinase Associated Lipocalin) is a novel biomarker that is being used to diagnose acute renal injury (AKI) early. Elevation of NGAL levels has been documented in the plasma and urine of animal models of ischemic and nephrotoxic AKI. Therefore, NGAL is also considered a novel urinary biomarker for ischemic injury. The loop of the Henle, the thick ascending limb, and the intercalated cells of the collecting duct are the primary areas of NGAL production in the kidney.
NGAL is also helpful in reducing an injury by stopping apoptosis and increasing the normal proliferation of kidney tubule cells. More specifically, NGAL has been reported to up-regulate heme-oxygenase-1, which preserves proximal tubule N-cadherin and inhibits cell death.
The rising research for NGAL testing and the approvals from the regulatory agencies for the NGAL tests are anticipated to increase the adoption of NGAL tests, thereby boosting the segment growth. For instance, in December 2023, Bioporto received United States Food and Drug Administration 510(k) approval for the NGAL biomarker for acute kidney injury (AKI) biomarker test for pediatric use in the United States.
Furthermore, the rising strategic partnerships for the development of NGAL biomarkers are anticipated to increase the adoption of this test to diagnose AKI, thereby boosting the segment growth. For instance, in February 2024, BioPorto A/S entered a collaboration with Roche Diagnostics to commercialize BioPorto's NGAL test as ProNephro AKI (NGAL) on Roche's cobas c 501 platform. Such commercialization agreements help increase NGAL testing adoption, driving the segment growth.
Additionally, the rising importance of NGAL testing in patients with contrast-induced acute kidney injury (CI-AKI) is anticipated to boost the segment growth further. According to the study published in the Diagnostics Journal in March 2023, the diagnostic efficacy of NGAL is outstanding. NGAL may act as a reliable biomarker for the early diagnosis of clinical and subclinical forms of renal injury after contrast angiography. Therefore, the high clinical diagnosis performance of NGAL biomarkers in assessing renal disease is anticipated to boost the demand for the segment studied, surging the market expansion.
Hence, with growing research and development activities, strategic partnerships for the development of NGAL, and the significance and efficacy of NGAL in detecting kidney conditions, the segment is expected to have steady growth over the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same Over the Forecast Period
North America currently holds a significant share of the market for renal biomarkers, and it is expected to continue its stronghold over the forecast period. The United States holds the largest market share in the North American region. In the past decade, there has been a significant increase in the number of FDA approvals containing information on molecular biomarkers. Almost every pharmaceutical company has been developing molecular biomarker programs through partnerships or other ventures.
The rising prevalence of chronic kidney disorders among people in the United States is a major factor attributed to the increasing usage of renal biomarkers for effective diagnosis and to boost the market growth in this region. For instance, according to the data published by the Centers for Disease Control and Prevention (CDC) in May 2023, 14.0% of adults in the United States, i.e., about 35.5 million, are estimated to have chronic kidney disease.
Additionally, the increasingly vulnerable aging population that is prone to chronic kidney diseases in the United States is also contributing to the rising demand for early-stage diagnosis and effective treatment, thereby contributing to the growth of the market. For instance, according to the data published by the Centers for Disease Control and Prevention (CDC) in May 2023, chronic kidney disease is accounted to be the most common in people aged 65 years or older, contributing to 34.0% of the affected population in the United States. Such a high prevalence of chronic kidney disease is projected to drive the adoption of effective diagnostic options, thereby influencing market growth.
Furthermore, the increasing focus of government agencies in the United States on developing and improving diagnostic tests for kidney diseases eventually increases the demand for renal biomarkers. For instance, in December 2023, the National Institute of Standards and Technology (NIST) developed the first human urine standard with precise measurements of albumin, a biomarker used to check the functionality of the kidneys. The standard will support decisions for diagnosing kidney diseases and improve health outcomes for people. Such government initiatives for improving the accuracy of diagnosing and managing kidney diseases are projected to drive the growth of renal biomarkers in the country.
Moreover, strategic activities adopted by the market players, such as Food and Drug Administration (FDA) approvals, product launches, and clinical trials, are expected to boost the market growth over the forecast period. For instance, in February 2023, Aravive Inc. demonstrated positive results from the Phase 1b/2 trial of batiraxcept in clear cell renal cell cancer (ccRCC) and a biomarker-high subgroup at the 2023 ASCO Genitourinary (GU) Cancers Symposium in the United States. Therefore, such clinical trials will boost the development of biomarker tests in the country. This will subsequently drive market growth.
Major companies are strategically entering into partnerships and collaborations with mid-sized companies in renal biomarkers to broaden the products and services offered by the company. For instance, in January 2024, LifeLabs, a Canada-based healthcare management and laboratory services provider, partnered with Klinrisk, a Canadian AI-based medical device company focused on improving the early detection and treatment of chronic kidney disease (CKD) through the groundbreaking Klinrisk Score. Klinrisk test analyzes routine blood and urine samples. It delivers a comprehensive report indicating the risk of progression for kidney function loss of up to 40% or kidney failure in the next five years. LifeLabs and Klinrisk join forces to revolutionize chronic kidney disease care. Such strategic initiatives are projected to drive market growth. These strategic activities would further increase the availability of renal biomarkers in the region, contributing to the market’s growth.
Thus, owing to the rising prevalence of chronic kidney disease, the increasing focus of government agencies on developing diagnostic tests, and strategic activities such as FDA approvals, clinical trials, and new product launches and partnerships by the market players in North America, the market is expected to witness a significant growth rate over the forecast period.
Renal Biomarkers Industry Segmentation
The renal biomarkers market is highly competitive and consists of several major players, along with multiple smaller companies. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new technologies at affordable prices. Companies like Thermofisher Scientific, Abbott Laboratories, Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, and BioMérieux hold substantial shares in the market.
Renal Biomarkers Market Leaders
-
Thermo Fischer Scientific Inc.
-
Abbott Laboratories
-
F. Hoffmann-La Roche AG
-
bioMérieux SA
-
Siemens Healthineers
*Disclaimer: Major Players sorted in no particular order
Renal Biomarkers Market News
- In January 2024, LifeLabs, a Canada-based healthcare management and laboratory services provider, partnered with Klinrisk, a Canadian AI-based medical device company focused on improving the early detection and treatment of chronic kidney disease (CKD) through the groundbreaking Klinrisk Score. Klinrisk test analyzes routine blood and urine samples.
- In January 2023, Renalytix PLC launched PRIME-CKD, which aims to validate and implement the product in clinical practice and novel biomarker-based tests for predicting the response to existing drugs used by patients with chronic kidney disease (CKD).
Renal Biomarkers Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Various Kidney-related Diseases
4.2.2 High Prevalence of Diabetes and High Blood Pressure, the Leading Cause of Renal Diseases
4.2.3 Rapid Technological Advances in the Field of Genetics
4.3 Market Restraints
4.3.1 Issues Related to Regulatory and Reimbursement Systems
4.4 Porter Five Forces
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products/Services
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Biomarker Type
5.1.1 Functional Biomarker
5.1.1.1 Serum Creatinine
5.1.1.2 Serum Cystatin C
5.1.1.3 Urine Albumin
5.1.2 Up-regulated Protein
5.1.2.1 Neutrophil Gelatinase-Associated Lipocalin (NGAL)
5.1.2.2 Kidney Injury Molecule-1
5.1.2.3 INTERLEUKIN-18
5.1.3 Other Biomarker Types
5.2 By Diagnostic Technique
5.2.1 Enzyme-linked Immunosorbent Assay
5.2.2 Particle-enhanced Turbidimetric Immunoassay (PETIA)
5.2.3 Colorimetric Assay
5.2.4 Chemiluminescent Enzyme Immunoassay (CLIA)
5.2.5 Liquid Chromatography Mass Spectrometry (LS-MS)
5.3 By End User
5.3.1 Hospitals
5.3.2 Diagnostic Laboratories
5.3.3 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 BioPorto Diagnostics AS
6.1.3 F. Hoffmann-La Roche AG
6.1.4 Thermo Fisher Scientific Inc.
6.1.5 SEKISUI MEDICAL CO., LTD.
6.1.6 BioMérieux
6.1.7 Sphingotec GmbH
6.1.8 Randox Laboratories Ltd
6.1.9 Siemens Healthineers AG
6.1.10 Enzo Life Sciences, Inc.,
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Renal Biomarkers Industry Segmentation
As per the scope of the report, renal biomarkers are biomarkers that help diagnose or identify patients at risk of developing kidney diseases by measuring their blood or urine levels. They are commonly released in acute or chronic kidney injuries, which are characterized by the rapid or gradual loss of kidney function, resulting in serious clinical implications. The renal biomarkers market is segmented by biomarker type, diagnostic technique, end user, and geography.
The market is segmented as a functional biomarker, up-regulated protein, and other biomarker types based on biomarker type. Based on diagnostic technique, the market is segmented as enzyme-linked immunosorbent assay, particle-enhanced turbidimetric immunoassay (PETIA), colorimetric assay, chemiluminescent enzyme immunoassay (CLIA), and liquid chromatography-mass spectrometry (LS-MS). Based on end-users, the market is segmented as hospitals, diagnostic laboratories, and other end users. The market is segmented based on geography into North America, Europe, Asia-Pacific, the Middle East, Africa, and South America. The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (in USD) for the above segments.
| By Biomarker Type | |||||
| |||||
| |||||
| Other Biomarker Types |
| By Diagnostic Technique | |
| Enzyme-linked Immunosorbent Assay | |
| Particle-enhanced Turbidimetric Immunoassay (PETIA) | |
| Colorimetric Assay | |
| Chemiluminescent Enzyme Immunoassay (CLIA) | |
| Liquid Chromatography Mass Spectrometry (LS-MS) |
| By End User | |
| Hospitals | |
| Diagnostic Laboratories | |
| Other End Users |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Renal Biomarkers Market Research FAQs
How big is the Renal Biomarkers Market?
The Renal Biomarkers Market size is expected to reach USD 1.5 billion in 2024 and grow at a CAGR of 7.53% to reach USD 2.20 billion by 2029.
What is the current Renal Biomarkers Market size?
In 2024, the Renal Biomarkers Market size is expected to reach USD 1.5 billion.
Who are the key players in Renal Biomarkers Market?
Thermo Fischer Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, bioMérieux SA and Siemens Healthineers are the major companies operating in the Renal Biomarkers Market.
Which is the fastest growing region in Renal Biomarkers Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Renal Biomarkers Market?
In 2024, the North America accounts for the largest market share in Renal Biomarkers Market.
What years does this Renal Biomarkers Market cover, and what was the market size in 2023?
In 2023, the Renal Biomarkers Market size was estimated at USD 1.39 billion. The report covers the Renal Biomarkers Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Renal Biomarkers Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Renal Biomarkers Industry Report
Statistics for the 2024 Renal Biomarkers market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Renal Biomarkers analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
